EP4008322C0 - Lecithin-partikel im nanometer bereich als wirkstoffträger zur parenteralen verabreichung - Google Patents

Lecithin-partikel im nanometer bereich als wirkstoffträger zur parenteralen verabreichung

Info

Publication number
EP4008322C0
EP4008322C0 EP21175796.8A EP21175796A EP4008322C0 EP 4008322 C0 EP4008322 C0 EP 4008322C0 EP 21175796 A EP21175796 A EP 21175796A EP 4008322 C0 EP4008322 C0 EP 4008322C0
Authority
EP
European Patent Office
Prior art keywords
active ingredient
parenteral administration
nanometer range
ingredient carrier
lecithin particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP21175796.8A
Other languages
English (en)
French (fr)
Other versions
EP4008322A1 (de
EP4008322B1 (de
Inventor
Kathrin Mühlhölzl-Odörfer
Elke Horstkotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leon Nanodrugs GmbH
Original Assignee
Leon Nanodrugs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leon Nanodrugs GmbH filed Critical Leon Nanodrugs GmbH
Publication of EP4008322A1 publication Critical patent/EP4008322A1/de
Application granted granted Critical
Publication of EP4008322C0 publication Critical patent/EP4008322C0/de
Publication of EP4008322B1 publication Critical patent/EP4008322B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21175796.8A 2020-05-25 2021-05-25 Lecithin-partikel im nanometer bereich als wirkstoffträger zur parenteralen verabreichung Active EP4008322B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20176364 2020-05-25

Publications (3)

Publication Number Publication Date
EP4008322A1 EP4008322A1 (de) 2022-06-08
EP4008322C0 true EP4008322C0 (de) 2024-11-27
EP4008322B1 EP4008322B1 (de) 2024-11-27

Family

ID=70804602

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21175796.8A Active EP4008322B1 (de) 2020-05-25 2021-05-25 Lecithin-partikel im nanometer bereich als wirkstoffträger zur parenteralen verabreichung

Country Status (1)

Country Link
EP (1) EP4008322B1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
JP2002540930A (ja) * 1999-04-08 2002-12-03 ペント ベルント 化学的プロセスおよび物理的プロセスを実施するための方法および装置
DE10124952A1 (de) * 2001-05-21 2002-12-12 Bayer Ag Verfahren zur Herstellung von Nanodispersionen
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
EP3270891A1 (de) * 2015-03-17 2018-01-24 Leon-Nanodrugs GmbH Nanopartikel mit einer stabilisierten boronsäureverbindung
DE102017210202A1 (de) 2017-06-19 2018-12-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Fluidreaktor

Also Published As

Publication number Publication date
EP4008322A1 (de) 2022-06-08
EP4008322B1 (de) 2024-11-27

Similar Documents

Publication Publication Date Title
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
CY1122617T1 (el) Απαλλαγμενες prion συνθεσεις νανοσωματιδιων και μεθοδοι
IN2014DN06529A (de)
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
HK1218506A1 (zh) 治療黑素瘤的方法
HK1209343A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
HK1208162A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
IN2014MN01575A (de)
SMT201600157B (it) Composti di carbammoilpiridone policiclici e loro uso farmaceutico
MX386982B (es) Métodos y composiciones relacionadas con nanoportadores sintéticos con rapamicina en un estado estable, súper-saturado.
PE20131166A1 (es) Formulacion de premezcla de dexmedetomidina
EP2873646A4 (de) Porösem siliziumteilchen, verfahren zu ihrer herstellung und anodenaktives material damit
WO2012094620A8 (en) Hydrophobic molecule-induced branched polymer aggregates and their use
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
WO2015081257A3 (en) Aminopyridine derivatives as tam family kinase inhibitors
WO2014099119A3 (en) Articles of apparel with garment components and pad components
EP3449944A4 (de) Oral verabreichte nanopartikel zur genverabreichung und pharmazeutische zusammensetzung damit
UY35824A (es) Preparación farmacéutica y forma de su producción y uso
JOP20200004A1 (ar) تركيبات طويلة المفعول
WO2015041809A3 (en) Small molecule cellular reprogramming to generate neuronal cells
ZA201807446B (en) Improved drug formulations
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
EP4008322C0 (de) Lecithin-partikel im nanometer bereich als wirkstoffträger zur parenteralen verabreichung
MX371297B (es) Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.
IT1401289B1 (it) Composti dotati di attivita' antiossidante nei confronti dei radicali liberi, e composizioni farmaceutiche e cosmetiche che li contengono

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221208

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LEON-NANODRUGS GMBH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009500000

Ipc: A61K0009000000

Ref country code: DE

Ref legal event code: R079

Ref document number: 502021005926

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0009500000

Ipc: A61K0009000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/51 20060101ALI20240610BHEP

Ipc: A61K 9/50 20060101ALI20240610BHEP

Ipc: A61K 9/00 20060101AFI20240610BHEP

INTG Intention to grant announced

Effective date: 20240628

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HORSTKOTTE, ELKE

Inventor name: MUEHLHOELZL-ODOERFER, KATHRIN

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502021005926

Country of ref document: DE

Owner name: LEON-NANODRUGS GMBH, DE

Free format text: FORMER OWNER: ANMELDERANGABEN UNKLAR / UNVOLLSTAENDIG, 80297 MUENCHEN, DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502021005926

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20241211

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20241220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250327

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 5

Effective date: 20250602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250527

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250601

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250521

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20250828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241127